TRAX

Conviction 100HealthcareScan · Thu, Sep 24, 2026

First Tracks Biotherapeutics, Inc. (TRAX) closed at $35.82 (-2.29%) on Sep 24, 2026. Price is below its 50-day. RSI(14) 40, -25.3% from its 52-week high, +92.6% year to date. Sector: Healthcare · Biotechnology.

TRAX$35.82-2.29%

ResistanceSupportVol 14

Vol MA14 789.14K

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

First Tracks Biotherapeutics, Inc.Biotechnology

Price35.82

Change-2.29%

Gap-0.27%

Rel volume2.26×

Avg volume758.01K

Avg $ vol30.13M

SMA 2039.95

SMA 5041.68

SMA 200—

Price vs 50-14.06%

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 45.06

RSI (14)40

MACD hist-0.41

MACD cross—

Stoch %K / %D13 / 23

ADX (14)17

+DI / −DI21 / 26

RSI divergenceBearish

MACD divergenceBullish

ATR %8.69%

ADR %7.20%

52w high47.92

52w low15.32

From 52w high-25.25%

Above 52w low+133.81%

New 52w highNo

SqueezeOff

Bollinger width25.31%

%B0.09

Donchian pos8.71%

Donchian high47.98

Donchian low34.66

AVWAP (52w high)41.57

vs AVWAP high-13.83%

AVWAP (52w low)34.11

vs AVWAP low+5.00%

OBV trendDown

Chaikin MF (20)-0.40

Today vs 20d2.26×

Avg vol (14d)789.14K

Avg vol (20d)758.01K

Avg $ vol (20d)30.13M

Market cap1.28B

RS Rating—

RS 3m (vs SPY)+114.32%

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank13.4

1 week-8.62%

1 month-20.59%

3 months+118.81%

6 months—

1 year—

YTD+92.58%

P/E—

P/B7.58

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current14.28

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target—

Target upside—

Analyst rating—

Institutional100.73%

Ent. value1.11B

Revenue—

Net income-33.37M

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out34.89M

Employees—

ListedMon, Apr 6, 2026

Free float32.62M

Float %93.5%

Short interest4.03M

Days to cover7.2d

Short volume44.9%

Squeeze score68 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.95 vs −$0.74

Last surprise-28.4% miss

Setup gradeA+

Conviction100 / 100

Pattern quality—

Tech rank13.4 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance49.75

Support37.66

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in TRAX

All disclosures →

No recent disclosed trades by Congress in TRAX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in TRAX

Insider	Side	Shares	Value	Traded	Filed
Orwin John A Director · Restricted Stock Unit · 2026-09-15	Exercise	1.3K	—	2026-09-15	2026-09-17
Orwin John A Director · Common Stock · 2026-09-15	Exercise	1.3K	—	2026-09-15	2026-09-17
STONE BENJAMIN Chief Business Officer · Performance Stock Units · 2026-08-15	Grant	60.49K	—	2026-08-15	2026-08-18
Faga Daniel President, CEO · Performance Stock Units · 2026-08-15	Grant	193.57K	—	2026-08-15	2026-08-18
Lizzul Paul F. Chief Medical Officer · Performance Stock Units · 2026-08-15	Grant	60.49K	—	2026-08-15	2026-08-18
Faga Daniel President, CEO · Performance Stock Units · 2026-08-02	Grant	193.58K	—	2026-08-02	2026-08-05
STONE BENJAMIN Chief Business Officer · Performance Stock Units · 2026-08-02	Grant	60.49K	—	2026-08-02	2026-08-05
Lizzul Paul F. Chief Medical Officer · Performance Stock Units · 2026-08-02	Grant	60.49K	—	2026-08-02	2026-08-05
FENTON DENNIS M Director · Stock Option (right to buy) · 2026-05-12	Grant	42K	$0	2026-05-12	2026-05-14
Faga Daniel President, CEO · Restricted Stock Unit · 2026-05-12	Grant	100.2K	$0	2026-05-12	2026-05-14

SEC filings

EDGAR filings in TRAX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.